Grants Funded
Grant applicants for the 2024 cycle requested a total of nearly $3 million dollars. The PSF Study Section Subcommittees of Basic & Translational Research and Clinical Research evaluated more than 100 grant applications on the following topics:
The PSF awarded research grants totaling over $650,000 dollars to support more than 20 plastic surgery research proposals.
ASPS/PSF leadership is committed to continuing to provide high levels of investigator-initiated research support to ensure that plastic surgeons have the needed research resources to be pioneers and innovators in advancing the practice of medicine.
Research Abstracts
Search The PSF database to have easy access to full-text grant abstracts from past PSF-funded research projects 2003 to present. All abstracts are the work of the Principal Investigators and were retrieved from their PSF grant applications. Several different filters may be applied to locate abstracts specific to a particular focus area or PSF funding mechanism.
A Peptide-Impregnated Gel for Accelerating Wound Tensile Strength Reestablishment
Principal Investigator
Zhong Zheng PhD
Zhong Zheng PhD
Year
2018
2018
Institution
The Regents of the University of California, Los Angeles
The Regents of the University of California, Los Angeles
Funding Mechanism
Translational Research Grant
Translational Research Grant
Focus Area
Wounds / Scar, Technology Based
Wounds / Scar, Technology Based
Abstract
Normal skin scarring and pathological hypertrophic scarring commonly occur after surgeries, especially in non-Caucasian patients (up to 47%), and often require multiple surgical revisions. To induce proper healing, the wound edges resulting from revision surgeries must be approximated with medical devices such as surgical sutures. The outcome of whether a sutured wound will heal with adequate tensile strength to prevent dehiscence or widened scars is largely dependent on factors such as tension, vascularity, and local cellular activity in the approximated wound. In cases accompanied by a lack of tissue, such as in cleft lip and palate revision, there is excessive tension across the wounds, making them more likely to succumb to wound dehiscence, one of the most serious postoperative complications that almost always leads to additional surgeries. Unfortunately, all available surgical suture devices approximate tissue in a purely mechanical, non-biological, fashion. Therefore, development of therapeutic suture devices that can accelerate tensile strength reestablishing in high risk, high tension wounds can significantly minimize wound dehiscence and hypertrophic scarring to improve functional and esthetic outcomes in revision surgeries. Towards this end, we have found that a 40-amino acid fibromodulin-derived peptide, F06-C40 can significantly promote fibroblast migration and increase wound tensile strength in both rodent and pig models. In addition, F06-C40-coated absorbable surgical sutures showed an increase in wound tensile strength by 50% vs. control non-peptide-coated sutures in porcine models preferred by the Food and Drug Administration for testing human cutaneous products. Given the broad indication for surgical sutures, we believe that a gel formulation that can be applied with any suture configuration may provide a more streamlined manufacturing strategy and more application flexibility for commercialization. Thus, the goal of the current PSF Translational Research Grant application is to develop and accomplish key efficacy objectives to expedite the commercialization of a peptide-impregnated gel-type device that can be applied with any suture configuration (with respect to needle specifications, suture composition and size) for accelerating wound tensile strength reestablishment and minimizing wound dehiscence. If successful, this product can significantly improve the quality of life of patients suffering from wound dehiscence or poor healing.
Normal skin scarring and pathological hypertrophic scarring commonly occur after surgeries, especially in non-Caucasian patients (up to 47%), and often require multiple surgical revisions. To induce proper healing, the wound edges resulting from revision surgeries must be approximated with medical devices such as surgical sutures. The outcome of whether a sutured wound will heal with adequate tensile strength to prevent dehiscence or widened scars is largely dependent on factors such as tension, vascularity, and local cellular activity in the approximated wound. In cases accompanied by a lack of tissue, such as in cleft lip and palate revision, there is excessive tension across the wounds, making them more likely to succumb to wound dehiscence, one of the most serious postoperative complications that almost always leads to additional surgeries. Unfortunately, all available surgical suture devices approximate tissue in a purely mechanical, non-biological, fashion. Therefore, development of therapeutic suture devices that can accelerate tensile strength reestablishing in high risk, high tension wounds can significantly minimize wound dehiscence and hypertrophic scarring to improve functional and esthetic outcomes in revision surgeries. Towards this end, we have found that a 40-amino acid fibromodulin-derived peptide, F06-C40 can significantly promote fibroblast migration and increase wound tensile strength in both rodent and pig models. In addition, F06-C40-coated absorbable surgical sutures showed an increase in wound tensile strength by 50% vs. control non-peptide-coated sutures in porcine models preferred by the Food and Drug Administration for testing human cutaneous products. Given the broad indication for surgical sutures, we believe that a gel formulation that can be applied with any suture configuration may provide a more streamlined manufacturing strategy and more application flexibility for commercialization. Thus, the goal of the current PSF Translational Research Grant application is to develop and accomplish key efficacy objectives to expedite the commercialization of a peptide-impregnated gel-type device that can be applied with any suture configuration (with respect to needle specifications, suture composition and size) for accelerating wound tensile strength reestablishment and minimizing wound dehiscence. If successful, this product can significantly improve the quality of life of patients suffering from wound dehiscence or poor healing.
Biography
Dr. Zhong Zheng received his BS in Biological Sciences and Biotechnology in 2001, and subsequently his MS and PhD in 2005, all from Tsinghua University in Beijing, China. Additionally, he received postdoctoral training in 2008-2012 from the Department of Orthopaedic Surgery of the UCLA David Geffen School of Medicine, as well as the Dental and Craniofacial Research Institute and Section of Orthodontics of the UCLA School of Dentistry. He currently is an Adjunct Assistant Professor at the UCLA School of Dentistry. He has been committed to using fibromodulin (FMOD) to manage skin wound healing processes, and has published related studies in the American Journal of Pathology and the Journal of Investigative Dermatology. Moreover, Dr. Zheng is the first person to generate the FMOD-related peptide to reduce scar formation. Currently, Dr. Zheng is focused on developing cell-based regenerative medicines for musculoskeletal tissue engineering, such as using human perivascular cells for bone regeneration. He also successfully reverted human fibroblasts into low tumorigenic multipotent cells with osteogenesis and myogenesis potential.
Dr. Zhong Zheng received his BS in Biological Sciences and Biotechnology in 2001, and subsequently his MS and PhD in 2005, all from Tsinghua University in Beijing, China. Additionally, he received postdoctoral training in 2008-2012 from the Department of Orthopaedic Surgery of the UCLA David Geffen School of Medicine, as well as the Dental and Craniofacial Research Institute and Section of Orthodontics of the UCLA School of Dentistry. He currently is an Adjunct Assistant Professor at the UCLA School of Dentistry. He has been committed to using fibromodulin (FMOD) to manage skin wound healing processes, and has published related studies in the American Journal of Pathology and the Journal of Investigative Dermatology. Moreover, Dr. Zheng is the first person to generate the FMOD-related peptide to reduce scar formation. Currently, Dr. Zheng is focused on developing cell-based regenerative medicines for musculoskeletal tissue engineering, such as using human perivascular cells for bone regeneration. He also successfully reverted human fibroblasts into low tumorigenic multipotent cells with osteogenesis and myogenesis potential.